Minoxidil vs Semax
FDA Approved vs Well Studied
monitor Mechanism-based · 51% Both Minoxidil and Semax can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Minoxidil Semax
Weight 209.25 Da 813.93 Da
Half-life ~4 hours (oral); topical effects persist significantly longer due to local tissue retention 0.5-2 hours
Chain — 7 amino acids
Type Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine) ACTH(4-10) synthetic analog
Key Benefits
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Semax
01 Rapid brain delivery via intranasal route
02 Rapidly increases BDNF levels
03 Extensive clinical research in Russia
04 Easy self-administration
05 Modulates dopamine and serotonin systems
06 Neuroprotective effects
Dosing Protocols
Minoxidil
Topical: 1mL of 5% solution twice daily / Oral: 1.25-2.5mg daily / Twice daily (topical) or once daily (oral)
Semax
300-600mcg per dose (up to 1000mcg for intensive use) / 1-2x daily (morning recommended for cognitive boost)
Research protocol 500-750mcg 1x daily
Intensive protocol 750-1000mcg 1-2x daily
Side Effects
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Semax
Mild nasal discomfort (nasal route)
Possible nasal sensation upon administration
Contraindications
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Pregnancy or breastfeeding
Known peptide allergies
Do not exceed 4-week continuous use without medical supervision
Research Evidence
Minoxidil Semax
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest — 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.